AstraZeneca achieves three significant milestones for blood thinner Brilique

10 May 2011

Anglo-Swedish drug major AstraZeneca (LSE: AZN) yesterday announced three items of news regarding its potential blockbuster blood thinner Brilique/Brilinta (ticagrelor), which late last year gained European Marketing approval (The Pharma Letter December 6, 2010) but is still awaiting clearance in the all-important US market.

The company said that new health economics data showed that treating a broad spectrum of acute coronary syndrome (ACS) patients with Brilique was more cost-effective than treatment with generic clopidogrel (Sanofi’s Plavix) based on the approved label in the European Union.

Additionally, it said that the Scottish Medicines Consortium (SMC) accepted Brilique for use and reimbursement for patients in Scotland, and the Ministry of Health and Prevention in Denmark also recently approved Brilique as the first branded oral antiplatelet therapy to achieve national reimbursement for a broad ACS population

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK